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The skin-sensitizing potential of chemicals is an important
concern for public health and thus a significant end point in the
hazard identification process. To determine skin-sensitizing
capacity, large research efforts focus on the development of
assays, which do not require animals. As such, an in vitro test has
previously been developed based on the differential expression of
CREM and CCR2 transcripts in CD341 progenitor-derived
dendritic cells (CD34-DC), which allows to classify chemicals as
skin (non-)sensitizing. However, skin sensitization is not an all-or-
none phenomenon, and up to now, the assessment of relative
potency can only be derived using the in vivo local lymph node
assay (LLNA). In our study, we analyzed the feasibility to predict
the sensitizing potency, i.e., the LLNA EC3 values, of 15 skin
sensitizers using in vitro data from the CD34-DC-based assay.
Hereto, we extended the in vitro–generated gene expression data
set by an additional source of information, the concentration of
the compound that causes 20% cell damage (IC20) in CD34-DC.
We statistically confirmed that this IC20 is linearly independent
from the gene expression changes but that it does correlate with
LLNA EC3 values. In a further analysis, we applied a robust
linear regression with both IC20 and expression changes of CREM
and CCR2 as explanatory variables. For 13 out of 15 compounds,
a high linear correlation was established between the in vitro
model and the LLNA EC3 values over a range of four orders of
magnitude, i.e., from weak to extreme sensitizers.
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Skin sensitization results from a series of immunological
events following skin contact with low–molecular weight
(MW) substances. A number of characteristics determine
whether a chemical can function as a contact sensitizer,
including the ability to penetrate the epidermis, react with
protein to form haptens, and further recognition of this
complex by immune cells. Up to now, the appraisal of the
skin-sensitizing capacity of chemicals has been evaluated by
in vivo animal tests (OECD, 2002). Because of the REACH
legislation, which stands in Europe since 1 June 2007, over
1,800,000 animals are estimated to have to be sacrificed for
determining whether or not a chemical is a skin sensitizer
(Rovida and Hartung, 2009). Because of the introduction of
such novel regulations and the growing public concern
regarding animal testing, the development of an in vitro test
to identify skin-sensitizing chemicals has become top priority.
VITOSENS is one of such newly developed in vitro assays that
models the immune recognition of chemical allergens in
dendritic cells (DCs), which are key immune cells involved in
skin sensitization. Microarray analyses revealed that in CD34þ
progenitor-derived DC (CD34-DC), the expression profiles of
cyclic adenosine monophosphate-responsive element mod-
ulator (CREM) and monocyte chemotactic protein-1 receptor
(CCR2) displayed highest discriminating potential between
chemical skin sensitizers and nonsensitizers after 6 h of
exposure. An initial study with 21 chemicals resulted in
a predictive power with a concordance of 89%, a specificity of
97%, and a sensitivity of 82% (Hooyberghs et al., 2008).
In the realm of the above-mentioned chemical regulation,
current risk management measures are mostly based on the
classification of chemicals as either sensitizers or nonsensi-
tizers. However, contact allergens vary substantially with
regard to their relative potency. Skin-sensitizing potency can be
defined as the relative ability of a chemical to induce skin
sensitization, which is determined by the amount of chemical
per unit area required for the acquisition of skin sensitization in
a previously naı¨ve individual (van Loveren et al., 2008). For
chemical safety assessment, it is of utmost importance to
evaluate dose-effect relationships and to classify chemicals
according to the strength of their response. Up till now, the
local lymph node assay (LLNA) is the only validated method
that has provided data that are suitable for comparing the
relative potencies of contact allergens. Basically, substances
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are identified as skin sensitizers in this assay if, at any test
concentration, they induce a threefold increase of lymph node
cell proliferation in mice compared with the vehicle control,
expressed as effective concentration (EC)3 (%). Thus, the
intrinsic sensitizing potency of a chemical is defined as
a function of the concentration required to elicit a threshold
positive response, a stimulation index equal to 3. For this
reason, the lower the EC3 value, the greater the relative skin-
sensitizing potency of the chemical (Gerberick et al., 2005).
Contact allergens that vary 10-fold in EC3 value are then
assigned to one of these four subcategories identified with the
descriptors ‘‘extreme’’ (EC3 < 0.1%), ‘‘strong’’ (0.1%  EC3
< 1%), ‘‘moderate’’ (1%  EC3 < 10%), and ‘‘weak’’ (10% 
EC3  100%) (Kimber et al., 2003).
Consequently, a new intriguing question arose: Which
critical events are triggered during the induction of skin
sensitization that correlates quantitatively with potency?
Identification of such events would aid in more accurate
predictions of the skin-sensitizing potency of a chemical. DC
activation upon allergen recognition is one such possibility,
which is the underlying immune reaction event of the
VITOSENS assay. Although this activation is often considered
as a readout for hazard identification and not risk (Kimber
et al., 2009), Gildea et al. (2006) observed measurable
differences in gene expression changes in DC depending on
the potency class of the inducer when applied at a dose that
induced 20% cell death. Other evidence that rewards
a potency-dependent response in DC is the supposition that
chemicals that are stronger sensitizers are also more capable of
producing danger signals (Basketter et al., 2007). This
coincides with Matzinger’s ‘‘danger hypothesis,’’ which states
that besides allergen recognition, also direct damage of DC or
other cells must occur to achieve DC activation (Gallucci and
Matzinger, 2001).
To evaluate the prospects of the VITOSENS assay toward
potency classification, we explored whether the differential
expression of the biomarker genes displays opportunities for
categorization of relative sensitization potency. To this end,
CD34-DC were exposed to 15 chemicals identified by LLNA
studies as weak, moderate, strong, and extreme sensitizers and
their in vitro–generated responses were correlated with in vivo
obtained EC3 values.
MATERIALS AND METHODS
Chemical compounds. The selection of the chemical compounds was
based on of a number of criteria. First of all, the compound had to be recognized
as a sensitizer by the LLNA and VITOSENS assays. To correlate the in vitro
data to relative in vivo skin-sensitizing potency, LLNA EC3 values on each
compound were required (National Institutes of Environmental Health
Sciences, 1999) (Gerberick et al., 2005). Furthermore, the set of chemicals
was chosen to cover the whole range from weak to extreme sensitizing
compounds. The chemicals were selected for their physicochemical parameters
to favor skin penetration (MW and logKo/w values) (Smith Pease et al., 2003).
This resulted in a set of 15 chemicals shown in Table 1. All chemicals were
purchased at highest possible purity from Sigma-Aldrich (St Louis), except for
Bandrowski’s Base (Apollo Scientific, Cheshire, UK).
Cell culture. CD34þ cell isolation and culture procedures have been
described before (Schoeters et al., 2007). Briefly, human cord blood samples
TABLE 1
Chemical Data Set for Potency Classification
Chemical CAS N EC3 (%) MW LogKo/w IC20 (lg/ml)
Oxazolone (Oxa) 15646-46-5 0.003 217.22 1.51 5 3 101
Dinitrofluorobenzene (DNFB) 70-34-8 0.030 186.1 1.83 2 3 100
Bandrowski’s Base (BB) 20048-27-5 0.030 318.38 No CAS match 1 3 101
Dinitrochlorobenzene (DNCB) 97-00-7 0.060 202.55 2.27 4 3 100
Dihydroquinone (DHQ) 123-31-9 0.110 110.11 1.03 6 3 100
Methyldibromoglutaronitrile (MdBG) 35691-65-7 0.900 265.93 1.63 2 3 101
2-mercaptobenzothiazole(2-MBT) 149-30-4 1.700 167.24 2.86 7 3 101
Dinitrobenzenesulfonic acid (DNBS) 885-62-1 2.000 270.15 3.32 6 3 101
Cinnamaldehyde (CA) 104-55-2 3.000 132.16 1.82 1 3 101
Nickel sulfate (Nickel) 10101-97-0 4.800 262.85 No CAS match 2 3 102
Tetramethylthiuram disulfide (TMTD) 137-26-8 5.200 240.43 1.7 2 3 102
Eugenol (Eug) 97-53-0 13.000 164.2 2.73 6 3 101
Citral 5392-40-5 13.000 152.24 3.45 1 3 102
Cinnamic Alcohol (CiAlc) 104-54-1 21.000 132.16 1.84 1 3 104
Geraniol 106-24-1 26.000 154.25 3.47 1 3 103
Note. Chemicals were selected for and ranked by their sensitizing capacity as was identified by their threefold stimulation of lymph node proliferation (EC3) in
the LLNA (NIH Publication N 99-4494 on the LLNA, 1999) (Gerberick et al. 2005). The extreme sensitizing chemicals are listed on top (EC3 > 0.1%), followed
by the strong (0.1%  EC3 < 1%), moderate (1%  EC3 < 10%), and weak (10%  EC3  100%) sensitizers. Physicochemical properties such as MW and
estimated octanol-water partition (logKo/w) coefficients were derived from the Episuite 4.0 software (Environmental Protection Agency). ‘‘No CAS match’’
indicates that no results could be retrieved for this chemical in the software. The mean concentration needed to induce 20% cytotoxicity in CD34-DC (IC20) was
derived from experiments on three independent donor samples.
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were collected from the umbilical blood vessels of placentas of normal full-
term infants. Informed consent was given by the mothers, and the study was
approved by the ethical commission of the Heilig Hart Hospital at Mol,
Belgium, and the St Dimpna Hospital in Geel, Belgium. Mononuclear cells
were separated from the cord blood by density gradient centrifugation, and
subsequently, CD34þ progenitor cells were extracted by positive immuno-
magnetic selection. These cells were cultured in Iscove’s modified Dulbecco’s
medium (Invitrogen, San Diego) in the presence of granulocyte/macrophage
colony stimulating factor (Gentaur, Brussels, Belgium), stem cell factor
(Biosource, Nivelles, Belgium), tumor necrosis factor-a (Roche Applied
Science, Upper Bavaria, Germany), and interleukin 4 (Biosource) to induce
proliferation and differentiation toward immature CD34-DC according to the
method described by Lardon et al. (1997). After differentiation, CD34-DC were
assessed for phenotypical properties of myeloid DC as was described before
(De Smedt et al., 2005; Nelissen et al., 2009). Flow cytometry data are
provided as supplemental material (Supplementary figure 1).
Chemical exposure. At the end of the 12-day culture period, the viability
of the cells was assessed using propidium iodide staining and immature DC
(4 3 106 cells/4 ml/well) from the same donor were exposed to the
15 chemicals in 6-well plates. As was previously published, the predictive
capacity of the VITOSENS assay was assessed by a cross-validation based on
the gene expression at the time points 6, 11, and 24 h. Later, we repeated the
cross-validation using each of the time points separately. The predictive
capacity of the model based solely on the 6-h data was equal to that of the
original model. For this reason and for practical considerations, the 6-h
exposure and not the 11 and 24 h was retained in the final setup of the
VITOSENS assay (Hooyberghs et al., 2008). The concentrations of the test
compounds used in exposure experiments yielded 20% cell growth inhibition or
cell death as compared with solvent-treated cells (20% inhibitory concentration,
IC20) at 24 h, as was previously determined on at least three biological donor
samples by propidium iodide staining, alamarBlue, or WST-1 cytotoxicity
assays. IC20 values are listed in Table 1. For each chemical and its
corresponding solvent, DC of at least three independent donors were exposed.
Dihydroquinone, dinitrobenzene sulfonic acid (DNBS), and nickel sulfate were
dissolved in cell culture medium, whereas the other chemicals were prepared in
a 100% dimethylsulfoxide (DMSO) stock solution and then further diluted in
medium with a final 0.05% (vol/vol) DMSO concentration. After 6 h of
exposure, the cell suspensions were collected, supernatants were removed by
centrifugation, and the cell pellets lysed in RLT Buffer (Qiagen, Hilden, The
Netherlands) containing 1% (vol/vol) 2-mercaptoethanol (Sigma-Aldrich).
Real-time RT-qPCR. Expression changes of the VITOSENS biomarker
genes with highest discriminating potential (CCR2 and CREM) were analyzed
(Hooyberghs et al., 2008). Total RNA was extracted from the cell lysates using
the RNeasy Mini Kit (Qiagen) according to the manufacturer’s instructions, and
quality was visually inspected for absence of degradation products using
agarose gel electrophoresis. For the complementary DNA (cDNA) synthesis,
1 lg of total RNA was used up to a total volume of 25.2 ll (diluted with RNase
free water). A mix of 4% (vol/vol) MgCl2 (125mM; Invitrogen), 10% (vol/vol)
PCR Buffer (103; Applied Biosystems, Lennik, Belgium), 10% (vol/vol)
dNTPs (40mM; Invitrogen), 5% (vol/vol) Random Hexamers (50lM), 5% (vol/
vol) RNase Inhibitor (20 U/ll), and 5% (vol/vol) MuLV Reverse Transcriptase
(50 U/ll, all from Applied Biosystems) was added to each RNA sample.
A protocol for cDNA synthesis was run on all samples (1 h at 42C, 5 min at
95C, and then put on hold at 4C). After cDNA synthesis, the samples were
diluted with Baxter water (Viaflo aqua ad injectabilia AUE0304) up to
a volume of 250 ll. Real-time reverse transcriptase (RT)-qPCR reactions
were then performed in 20 ll volume containing 20 ng cDNA, 12.5% (vol/vol)
103 PCR Buffer, 10% (vol/vol) dNTP (10mM), 7.5% (vol/vol) MgCl2 (50mM,
all from Invitrogen), 2.5% (vol/vol) of each primer (25mM; Eurogentec S.A.,
Seraing, Belgium), 0.625% (vol/vol) SYBR Green I nucleic acid gel strain
(5003; Molecular Probes, Leiden, The Netherlands), 1.25% (vol/vol)
fluorescein (100nM; Eurogentec s.a., Seraing, Belgium), and 0.625% (vol/
vol) Platinum Taq polymerase (5 U/ll; Invitrogen) in Baxter water. Samples
were denatured at 95C during 5 min. Subsequently, 40 PCR cycles were run
consisting of 1 min at 95C for denaturation, 1 min at the appropriate annealing
temperature, and 1 min at 72C for elongation. RT-qPCR reactions were run in
triplicate for each sample on a BioRad iCycler (BioRad, Nazareth, Belgium).
For each primer pair analyzed, a nontemplate control was run in parallel. After
amplification, a threshold was set for each primer and Cq values were
calculated for all samples. Primers were designed using Primer Express
Software v3.0 from Applied Biosystems and thoroughly tested (primer
sequences are available upon request). Gene expression changes were analyzed
using the Biogazelle qBasePlus software (www.qbaseplus.com; Biogazelle,
Ghent, Belgium) (Hellemans et al., 2007). The results were analyzed with the
DDCt method corrected for gene-specific efficiencies. Gene expression changes
were determined as fold changes (FC): ratios of gene expression levels of
exposed samples over corresponding solvent control samples. For each sample,
transcripts of five reference genes were measured (GAPDH, HPRT, SDHA,
RPLI3A, and YWHAZ), and their stability was assessed as described by
Vandesompele et al. (2002). To achieve accurate FC, it was set as a criterion
that the normalization should be performed to a set of at least three stable
reference genes.
Statistical data analysis. All statistical analyses were performed using
Matlab2008b software (The MathWorks, Inc., Natick). For each evaluation, the
experimental data (EC3, IC20, and gene expression FC) were logarithmically
transformed in order to have distributions that are closer to Gaussian ones.
Moreover, in the linear regression analyses, the use of logarithmic variables is
needed to have an approximate homoscedastic variance. If the regression was
performed without logarithmic transformation, the resulting correlation would
be artificially high because it would be dominated by a few points in the high
value range of the variables. In such a case, the regression would overfit these
data points, whereas the rest of the data would all cluster close to the origin.
Ordinary least squares linear regression analyses. An ordinary least
squares linear regression analysis was used to measure the correlation between
both the EC3 values (%) and the linear fit of the FC of CREM and CCR2 and
between EC3 and IC20 (lg/ml) for the chemical sensitizers. Per chemical, the
mean log FC or log IC20 of three independent experiments was considered.
Both the Pearson and the Spearman rank correlation coefficients were calculated.
The correlation between the IC20 and the FC of CREM and CCR2 was also
evaluated and was quantified by the variance inflation factor (VIF) (see below).
Variance inflation factor. The VIF is a measure to assess the multi-
collinearity of the explanatory (or the independent) variables in an ordinary
least squares regression analysis. It was used to avoid the inclusion of
explanatory variables that are highly correlated because this would lead to
unstable estimates of the regression coefficients. The explanatory variables that
were considered for this analysis are the IC20 and the FC of CREM and CCR2.
The VIF for each explanatory variable Xi is defined as VIFi ¼ 11R2i ; where
Ri is the correlation coefficient of an ordinary least square regression with Xi as
a function of the other variable Xj. When Xi cannot be predicted by the other Xj,
the R2i will be close to 0 and the VIF close to 1. A higher VIF indicates a higher
multicollinearity, and a common rule of thumb is that multicollinearity is high
when VIF > 5.
Cook’s distance and leverage. Cook’s distance is an estimate of the
influence of a data point in least squares regression. It measures the effect of
deleting a given observation on the residuals of all other observations, a higher
distance indicates a more influential point.
Leverage points are those observations made at outlying values of the
independent explanatory variables, such that the lack of neighboring
observations means that the fitted regression model will pass close to that
particular observation. If a point has large leverage, then the slope of the
regression line follows more closely the slope of the line between that point and
the mean point.
M-estimation robust multiple linear regression. Standard linear re-
gression models are based on certain assumptions, such as a Gaussian
distribution of errors in the observed responses. If the distribution of errors is
124 LAMBRECHTS ET AL.
 at Universiteit M
aastricht on June 29, 2010 
http://toxsci.oxfordjournals.org
D
ow
nloaded from
 
heavy tailed or prone to outliers, model assumptions are invalid and parameter
estimates become unreliable. A possible alternative is the use of robust
regression models, which are less sensitive to outliers. In the current paper,
M-estimation robust multiple linear regression is implemented, which operates
by assigning a weight to each data point. Weighting is done by the iteratively
reweighted least squares method. In the first iteration, each point is assigned
equal weight and model coefficients are estimated using ordinary least squares.
At subsequent iterations, weights are recomputed so that points farther from
model predictions in the previous iteration are given lower weight. Model
coefficients are then recomputed using weighted least squares. The process
continues until the values of the coefficient estimates converge within
a specified tolerance. Technically, the weights were assigned by the bisquare
objective function with a biweight tuning constant of 3.
RESULTS
In the current paper, we analyzed the feasibility to apply data
obtained by the in vitro VITOSENS assay in a fit to the in vivo
derived potency of skin sensitizers, determined by the EC3
value of the LLNA. For this research, only sensitizers were
retained, which implies that in an operational setup, a compound
is only allowed to enter the current potency evaluation if it was
previously classified as a sensitizer by the VITOSENS assay.
To this end, RNA samples were generated from CD34-DC
that were exposed for 6 h to the IC20 concentration of 15
sensitizing chemicals, and gene expression FC of the markers
CREM and CCR2 as compared with solvent-treated cells were
obtained using real-time RT-qPCR. Per compound, the gene
expression measurements were independently performed on
DC from at least three donors. The resulting mean logarithmic
FC of CREM and CCR2 are presented as supplemental data
(Supplementary figures 2 and 3). In a first statistical analysis
approach, the data on gene expression changes of CREM and
CCR2 were compared with the LLNA EC3 values. Figure 1
presents the results of an ordinary least squares linear
regression analysis between the chemical-induced FC in
CD34-DC and the EC3 value. For visual simplicity, only the
mean value of the modeled potency per compound is plotted.
Although the chemicals oxazolone (Oxa), dinitrochlorobenzene
(DNCB), and cinnamic alcohol (CiAlc) distort the relation, an
interdependence between both variables is clearly observed.
The Spearman rank correlation coefficients and Pearson
correlation coefficients (R) are 0.26 and 0.13, respectively.
The presence of outlying chemicals may be brought on by
the deficit of explanatory variables. To this end, we extended
the gene expression data set of the 15 sensitizers by an
additional source of in vitro information, the compound’s
ability to induce damage to CD34-DC. As an (inverse) measure
of cell damage potency, we used the chemical concentration
that induces 20% cell death or cell growth inhibition (IC20).
There are reasons to assume that the IC20 and FC in our assay
are independent to a certain degree. First, in our assay,
exposure for gene expression measurement occurred at a pre-
viously determined chemical-specific IC20 level; hence, in
theory, all the exposed cultures experience a level of damage,
which is equal and independent of the applied compound.
Second, it has been postulated before that the danger effect
a compound induces because of damage is strongly related to
the exposure concentration of an allergen, whereas the
antigenic properties are to a lesser extent related to concentra-
tion. Therefore, we assume that because we created an equal
level of danger for all chemicals in this setup, the compound-
specific response of DC, here the FC of CREM and CCR2, is
dependent on the compound-specific antigenic signal and not
on the compound-specific danger-inducing IC20. One way to
statistically assess this independence is by evaluating the
multicollinearity through the VIF of the IC20 versus the FC of
CREM and CCR2. The resulting VIF ¼ 1.1 showed that the
IC20 is not linearly related to the FC, indicating that it
potentially possessed additional information worthwhile to
include in a model for potency prediction. Applying an
ordinary least squares linear regression analysis, we observed
a moderate correlation between CD34-DC-derived IC20 and
LLNA EC3 values for all 15 chemical sensitizers (Figure 2),
involving Spearman rank correlation coefficients and Pearson
correlation coefficients (R) of 0.60 and 0.73, respectively.
A trend toward a strong correlation is apparent, again with
outliers as, e.g., tetramethylthiuram disulfide (TMTD).
The next step would be to perform an ordinary least squares
regression analysis with both the IC20 and the FC of CREM
and CCR2 as explanatory variables for the dependent variable
EC3. However, ordinary least squares regression is known to
rely heavily on assumptions, which are often not met in
practice and perform poorly in the presence of outliers, either in
the explanatory variables or in the dependent variable.
Therefore, we first identified the impact of the data on the
regression analysis by calculating the leverage and Cook’s
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FIG. 1. Scatter plot of the linear fit results of the in vitro FC of CREM and
CCR2 versus the in vivo EC3 per compound. Mean FC values of three
independent experiments are used per chemical. Spearman rank correlation
coefficient ¼ 0.26 and Pearson correlation coefficient ¼ 0.13.
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distance. Figure 3 shows the result for the mean over the three
experimental replicates. A high Cook’s distance is an indicator
for high influence of a point on the regression parameters, and
in Figure 3a, the compounds Oxa and TMTD are identified
as such. In Figure 3b, the leverage per chemical is shown,
which is a measure for the outlying character of points in the
space of the explanatory variables; the dependent variable is
not considered in this measure. There are no pronounced
candidates in this sense, indicating the absence of compounds
with outlying IC20 or gene expression FC. TMTD and CiAlc
are on the high end, which is a consequence of their respective
extremely low and high IC20 values as can be seen in Figure 2.
Having observed a few outliers, it is advantageous to
perform a robust regression over ordinary least squares
regression. In the current study, an M-estimation robust linear
regression method was chosen, which iteratively reweights data
points giving less weight to outlying data, thereby significantly
improving the linear model for the remaining data. The result
of the robust linear regression with both the IC20 and the gene
expressions as input is shown in Figure 4, the inset explicitly
presents all replicate measurements, whereas the main pane
depicts the corresponding mean result per compound. All
replicate data points of Oxa and TMTD received a final zero
weight in the robust model and were marked as outliers. The
remaining compounds closely scattered around the identity
diagonal. The Spearman rank correlation coefficients and
Pearson correlation coefficients are, respectively, 0.91 and
0.79. The contribution of each variable was assessed by its
respective significance level; the IC20 had the largest impact
on the strong correlation estimates (p < 0.001), followed by the
FC of CREM (p ¼ 0.050) and CCR2 (p ¼ 0.166). In
conclusion, in vivo EC3 values of 13 out of 15 compounds
proved a strong linear correlation with IC20 values and gene
expression FC of CREM and CCR2 in in vitro–cultured CD34-
DC. The correlation is valid over four orders of magnitude in
EC3; this is over the entire range of the LLNA going from
weak to extreme sensitizers. Note that the residuals, i.e., the
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FIG. 2. Scatter plot of the linear fit results of the in vitro IC20 versus the
in vivo EC3 per compound. Spearman rank correlation coefficient ¼ 0.60 and
Pearson correlation coefficient ¼ 0.73.
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FIG. 3. The Cook’s distance (a) and leverage (b) per compound. Mean values derived from at least three different donors are shown per chemical.
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vertical deviations from the diagonal, are more or less equal
over the entire data range, which is a clear indication that the
use of logarithmic scales for the variables was needed (see
Statistical data analysis in ‘‘Materials and Methods’’ section).
Without the logarithmic transformation, the resulting correla-
tion would be higher, but the residuals would be dependent on
potency class, which is unwanted.
DISCUSSION
Using data obtained by the in vitro VITOSENS assay, we
aimed to establish a measure for skin-sensitizing potency in
correspondence with the EC3 values obtained by the LLNA.
This latter animal-based assay seeks to identify contact
allergens as a function of events induced during the acquisition
of skin sensitization, more specifically, lymphocyte prolifera-
tive responses induced in the regional lymph nodes of mice
exposed topically to test chemicals.
Earlier reports suggested that genes expressed in peripheral
blood monocyte–derived DC might also be capable of
classifying allergens into specific potency categories based
on relative differences in gene expression (Gildea et al.,
2006). This observation prompted us to investigate the
feasibility of assessing the potency of 15 skin-sensitizing
chemicals, which were identified as such by the VITOSENS
assay. As a first test in the setup, chemicals could be grouped
as sensitizers or not based upon the gene expression changes
of CREM and CCR2 (Hooyberghs et al., 2008). When in
a next step, compounds needed to be ranked according to their
sensitizing potency, these FC yielded insufficient information.
Therefore, we extended the gene expression data set by
another in vitro–generated variable, the concentration of the
test chemical that yielded 20% cell damage (referred to as
IC20). This inclusion is founded upon the danger hypothesis
by Matzinger, who described direct damage to DC as a danger
signal that might aid in the induction of maturation (Gallucci
and Matzinger, 2001). In vitro, this referred danger signal
may be translated as the mild cell cytotoxicity needed to
activate DC (Hulette et al., 2005). ANOVA inflation factors
revealed that both IC20 and gene expression changes are
linearly independent from one another and therefore could be
used as explanatory variables in a linear regression analysis.
This might not be surprising for two reasons. First, in our
setup, all exposures for gene expression measurement
occurred at an IC20, which consequently creates an equal
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level of cellular damage and this damage level is therefore
independent of the applied compound. Second, it has been
postulated that in vivo, the concentration of a hapten may be
related to its danger signal but may have less to do with
antigen signals (McFadden and Basketter, 2000). Therefore,
we assume that with an equal level of damage or danger, the
compound-specific response of DC (the FC of CREM and
CCR2) is rather dependent on the compound-specific antigen
signal and not on the compound-specific IC20. The relevance
of including IC20 as an explanatory variable was experimen-
tally demonstrated by a clear trend toward the chemical with
lower damaging dose also being more sensitizing.
Because ordinary least squares estimates are highly
susceptible to and biased by outliers, we applied a more
robust approach, i.e., M-estimation robust multiple linear
regression analysis. This analysis clearly confirmed the
deviate character of Oxa and TMTD, which also became
apparent by applying a Cook’s distance analysis. All other
data were correlated without accounting any weight to the
former compounds. For the remaining chemical sensitizers,
a potency value was modeled that closely fitted the in vivo
EC3 data, and this over the entire range from weak to
extremely sensitizing chemicals. This observation points to
the feasibility to classify sensitizers further into several
potency classes based on our in vitro data.
The identification of TMTD and Oxa as chemical
sensitizers with distorting impact on the regression fit might
indicate some limitations of the proposed model of skin-
sensitizing potency. TMTD was identified as a compound
with an extremely low IC20 value (0.024 lg/ml) in CD34-DC
and was therefore attributed a higher potency in our setup
than what was determined in vivo by the LLNA (Gerberick
et al., 2005). This finding might be an indication that the
model presented here is not suitable for classifying chemicals
with extreme IC20 values. Oxa, on the other hand, did not
exert cytotoxicity at extreme concentrations but nonetheless
appeared to behave as an outlier in the VITOSENS potency
classification. No data could be retrieved on the skin-
sensitizing potency in humans, whereas in the LLNA, Oxa
was identified as an extreme sensitizer based on its EC3
stimulation (Loveless et al., 1996). In our setup, however,
Oxa showed up merely as a moderate sensitizer. Besides
interspecies differences, a possible explanation for this
discrepancy is the fact that Oxa is a compound with poor
water solubility, which may mask it’s in vivo effects in a cell
culture environment. A similar phenomenon may occur
for DNCB and DNBS, the latter being the water-soluble
analogue of the former (Ryan et al., 2004). DNBS has
a negative logKo/w value and therefore poor lipid solubility.
This is probably the cause of the underestimation of the
potency difference between the two compounds in our assay.
Nonetheless, addition of the octanol-water partition coeffi-
cient (logKo/w) as an explanatory variable appeared not
sufficient (data not shown) to improve the fitted model.
Hence, besides expansion of the chemical data set, another
possible step to further optimize the current in vitro potency
classification is the inclusion of additional explanatory
variables that impact on the acquisition of skin sensitization.
Integration of parameters like epidermal disposition, peptide
reactivity, or T-cell proliferation may contribute in approx-
imating this biological complexity (Jowsey et al., 2006) and
may therefore aid in improving relative potency estimates.
A final observation is the close fit between VITOSENS and
LLNA skin-sensitizing potency of chemicals that require
metabolic activation to become an active sensitizer, so-called
prohaptens (e.g., eugenol, geraniol, and CiAlc). This suggests
that CD34-DC possess metabolic capacities.
In conclusion, we propose that besides the LLNA, an in vitro
assay based on the activation of primary DC may provide
valuable information in determining the relative potency of
chemical skin sensitizers. When a compound is being identified
as a skin sensitizer by the VITOSENS assay, further evaluation
of the obtained data quantitatively fits its sensitizing capacity
with strong correlation to the LLNA EC3 values. This holds for
the entire range of chemicals tested in the LLNA going from
weak, even including prohaptens, to extreme sensitizers.
Therefore, we believe that the VITOSENS assay offers
a relevant source of in vitro information for future identification
of safe-to-use exposure thresholds of potential skin sensitizers
and that the underlying event of DC activation is not an all-or-
none phenomenon. Further compound testing and character-
ization of the applicability domains, as well as limitations of
this model, are required to allow for in vitro potency
classification. Effective integration of VITOSENS in a test
battery alongside other test systems that reflect different steps
of the sensitization cascade may be a possible solution for
approximating the biological complexity of the process.
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